Important Safety Information
CAVERJECT should not be used in men hypersensitive to alprostadil, men with conditions that may predispose them to priapism (such as sickle cell anemia or trait, multiple myeloma or leukemia), men with anatomical deformities of the penis (such as angulation, cavernosal fibrosis or Peyronie’s disease), men with penile implants, or men for whom sexual activity is inadvisable or is contraindicated.
CAVERJECT should not be used in women, children or newborns.
Patients should be instructed to immediately report to his physician any erection lasting 4 hours or longer. If unavailable, patient must seek immediate medical assistance.
CAVERJECT can cause penile fibrosis or Peyronie’s disease.
Use of Caverject in patients who take anticoagulants, such as warfarin or heparin, should be with precaution as they may have increased tendency for bleeding after Caverject injections.
The most common side effect of CAVERJECT® (alprostadil for injection) was penile pain, reported by 37% of patients in clinical studies. Other side effects were prolonged erection, penile fibrosis and injection site hematoma. To lower the risk of prolonged erections or priapism, Caverject should be titrated slowly to the lowest effective dose.
For Full Prescribing Information for CAVERJECT®, including Instructions for Use, please click here.